Company profile for Atara Biotherapeutics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Atara Biotherapeutics (Nasdaq:ATRA) is a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases. The company was founded in 2012 and named after Atara Ciechanover who suffered from cancer before passing away.Originating from over a decade of groundbreaking clinical experience at Memorial Sloan Kettering and QIMR Berghofer, Atara’s off...
Atara Biotherapeutics (Nasdaq:ATRA) is a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases. The company was founded in 2012 and named after Atara Ciechanover who suffered from cancer before passing away.Originating from over a decade of groundbreaking clinical experience at Memorial Sloan Kettering and QIMR Berghofer, Atara’s off-the-shelf, allogeneic T cells are bioengineered from donors with healthy immune function and allow for rapid delivery from inventory to patients without a requirement for pretreatment.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
611 Gateway Blvd, Suite 900 South San Francisco, CA 94080
Telephone
Telephone
(650) 278-8930
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.businesswire.com/news/home/20251112949094/en/Atara-Biotherapeutics-Announces-Third-Quarter-Financial-Results-and-Operational-Progress

BUSINESSWIRE
12 Nov 2025

https://www.businesswire.com/news/home/20250903414165/en/Atara-Biotherapeutics-Announces-Changes-to-Its-Board-of-Directors

BUSINESSWIRE
03 Sep 2025

https://www.businesswire.com/news/home/20250811258417/en/Atara-Biotherapeutics-Announces-Second-Quarter-Financial-Results-and-Operational-Progress

BUSINESSWIRE
11 Aug 2025

https://www.prnewswire.com/news-releases/pierre-fabre-pharmaceuticals-inc-announces-transfer-of-investigational-new-drug-application-for-tabelecleucel-from-atara-biotherapeutics-inc-302504743.html

PR NEWSWIRE
15 Jul 2025

https://www.businesswire.com/news/home/20250714300738/en/Atara-Biotherapeutics-Provides-Regulatory-and-Business-Updates-on-Tabelecleucel-Tab-cel

BUSINESSWIRE
14 Jul 2025

https://www.businesswire.com/news/home/20250516069400/en/Atara-Biotherapeutics-Appoints-James-Huang-and-Nachi-Subramanian-to-Board-of-Directors

BUSINESSWIRE
16 May 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty